Combination CAR-T Cell Therapy Targeting Hematological Malignancies
ConditionB-cell Malignancies
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age6-75
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70 (4SCAR70) or CD123 (4SCAR123) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
Eligibility criteria
Qualifiers
age older than 6 months.
malignant B cell surface expression of CD19/CD20/CD22/CD30/CD38/CD70/CD123 molecules.
the KPS score over 80 points, and survival time is more than 1 month.
greater than Hgb 80 g/L.
Disqualifiers
accompanied with other active diseases, the treatment is difficult to assess patient response.
bacteria, fungus, or virus infection, unable to control.
living with HIV.
active HBV and HCV infection.
Trial design
Treatments tested in this trial
- 4SCAR19 and 4SCAR22
- 4SCAR19 and 4SCAR38
- 4SCAR19 and 4SCAR20
- 4SCAR19 and 4SCAR123
- 4SCAR19 and 4SCAR70
- 4SCAR19 and 4SCAR30
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov